Q2 2026 revenue was $783M, flat sequentially, with TYVASO pressured by competition but DPI showing growth. Major clinical milestones and regulatory filings position for multi-billion-dollar opportunities in PAH and IPF, with stronger performance expected in H2 2026.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.